Daniel O’Day
Chairman and Chief Executive Officer
Mr. O’Day joined Gilead Sciences in March 2019 as Chairman of the Board of Directors and Chief Executive Officer. Prior to Gilead, Mr. O’Day served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the company’s pharmaceutical and diagnostics divisions in North America, Europe and Asia. He served as a member of Roche’s Corporate Executive Committee, as well as on a number of public and private boards, including Genentech, Flatiron Health and Foundation Medicine. Mr. O’Day holds a bachelor’s degree in biology from Georgetown University and an MBA from Columbia University in New York. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America organization and Galapagos NV.
-
Daniel O’Day
Chairman and Chief Executive Officer
-
Jacqueline K. Barton, PhD
Professor, California Institute of Technology
-
Jeffrey A. Bluestone, PhD
President and Chief Executive Officer, Sonoma Biotherapeutics; A.W. and Mary Margaret Clausen Distinguished Professor in the Diabetes Center at University of California San Francisco
-
Sandra J. Horning, MD
Retired, Chief Medical Officer, Roche, Inc.; Emerita Professor, Stanford University
-
Kelly A. Kramer
Retired, Executive Vice President and Chief Financial Officer, Cisco Systems, Inc.
-
Kevin E. Lofton
Lead Independent Director; Retired Chief Executive Officer, CommonSpirit Health
-
Harish Manwani
Retired Chief Operating Officer, Unilever
-
Javier J. Rodriguez
Chief Executive Officer, DaVita Inc.
-
Anthony Welters
Chairman and Chief Executive Officer, CINQ Care Inc.; Executive Chairman, BlackIvy Group, LLC; Chairman, Somatus Inc.